A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent Vaccines With a Ready-to Use PCV2 and Bivalent Vaccine

Overview

Journal Front Vet Sci

Specialty Veterinary Medicine

Date 2020 Sep 28

PMID 32984414

Citations 5

Authors

Siyeon Yang

Taehwan Oh

Kee Hwan Park

Hyejean Cho

Chanhee Chae

Affiliations

Soon will be listed here.

Abstract

The present study evaluated the efficacy of swine vacciation using a combination of mixable monovalents for porcine circovirus type 2 (PCV2) and against a ready-to-use bivalent vaccine under experimental conditions. Pigs at 21 days of age were administered either a combination of two mixable monovalent vaccines or a bivalent vaccine containing PCV2 and . Vaccination was followed with an challenge at 42 days of age (-14 days post challenge, dpc) and a PCV2d challenge at 56 days of age (0 dpc). Each vaccinated and challenged group was compared with the unvaccinated and challenged group for clinical, microbiological, immunologic, and pathologic differences. Clinically, two vaccinated and challenged groups showed minimal respiratory diseases that was characterized by occasionally coughing and sneezing. A significant difference was not calculated in the average daily weight gain, nasal shedding of , and pathological lesions between two vaccinated and challenged groups. A combination of two monovalent vaccines mixed into a combo prior to vaccination followed by challenge resulted in increased numbers of PCV2d-specific interferon-γ secreting cells at 21 dpc and a significant reduction in PCV2d viremia at 14 dpc when compared with the ready-to-use bivalent-vaccinated and challenged groups. These results offer supporting evidence that vaccination during the weaning to finishing period against and PCV2 is efficacious for controlling diseases caused by these two pathogens.

Citing Articles

A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia.

Ham S, Suh J, Kim C, Seo B, Park G, Chae C Vet Med Sci. 2024; 10(5):e70001.

PMID: 39189840 PMC: 11348503. DOI: 10.1002/vms3.70001.

Evaluation of the protective efficacy of six major immunogenic proteins of .

Han S, Wang Y, Chang W, Wang L, Fang J, Han J Front Vet Sci. 2024; 10:1334638.

PMID: 38239753 PMC: 10794622. DOI: 10.3389/fvets.2023.1334638.

A Comparative Field Evaluation of the Effect of Growth Performance Between Porcine Circovirus Type 2a (PCV2a)- and PCV2b-Based Bivalent Vaccines Containing PCV2 and .

Cho H, Oh T, Suh J, Chae C Front Vet Sci. 2022; 9:859344.

PMID: 35812885 PMC: 9263624. DOI: 10.3389/fvets.2022.859344.

Comparative growth performance of 3 types of combination vaccines containing porcine circovirus 2 and under field conditions.

Yang S, Lee J, Oh T, Park K, Cho H, Suh J Can J Vet Res. 2022; 86(2):93-101.

PMID: 35388232 PMC: 8978288.

Efficacy of Two Commercial Ready-To-Use PCV2 and Vaccines under Field Conditions.

Lopez-Lorenzo G, Prieto A, Lopez-Novo C, Diaz P, Lopez C, Morrondo P Animals (Basel). 2021; 11(6).

PMID: 34073385 PMC: 8229604. DOI: 10.3390/ani11061553.

References

Djordjevic S, Eamens G, Romalis L, Nicholls P, Taylor V, Chin J . Serum and mucosal antibody responses and protection in pigs vaccinated against Mycoplasma hyopneumoniae with vaccines containing a denatured membrane antigen pool and adjuvant. Aust Vet J. 1997; 75(7):504-11. DOI: 10.1111/j.1751-0813.1997.tb14383.x. View

Van Reeth K, Nauwynck H, Pensaert M . A potential role for tumour necrosis factor-alpha in synergy between porcine respiratory coronavirus and bacterial lipopolysaccharide in the induction of respiratory disease in pigs. J Med Microbiol. 2000; 49(7):613-620. DOI: 10.1099/0022-1317-49-7-613. View

Galliher-Beckley A, Pappan L, Madera R, Burakova Y, Waters A, Nickles M . Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines. Vaccine. 2015; 33(25):2903-8. DOI: 10.1016/j.vaccine.2015.04.065. View

Opriessnig T, Thacker E, Yu S, Fenaux M, Meng X, Halbur P . Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and porcine circovirus type 2. Vet Pathol. 2004; 41(6):624-40. DOI: 10.1354/vp.41-6-624. View

Kim J, Chung H, Chae C . Association of porcine circovirus 2 with porcine respiratory disease complex. Vet J. 2003; 166(3):251-6. DOI: 10.1016/s1090-0233(02)00257-5. View

Chae C . Postweaning multisystemic wasting syndrome: a review of aetiology, diagnosis and pathology. Vet J. 2004; 168(1):41-9. DOI: 10.1016/j.tvjl.2003.09.018. View

Tao Y, Shu J, Chen J, Wu Y, He Y . A concise review of vaccines against Mycoplasma hyopneumoniae. Res Vet Sci. 2019; 123:144-152. DOI: 10.1016/j.rvsc.2019.01.007. View

Martelli P, Ferrari L, Morganti M, De Angelis E, Bonilauri P, Guazzetti S . One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet Microbiol. 2011; 149(3-4):339-51. DOI: 10.1016/j.vetmic.2010.12.008. View

Kim J, Chae C . Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 in porcine circovirus 2-induced granulomatous inflammation. J Comp Pathol. 2004; 131(2-3):121-6. DOI: 10.1016/j.jcpa.2004.02.001. View

10.

Mankertz A, Persson F, Mankertz J, Blaess G, Buhk H . Mapping and characterization of the origin of DNA replication of porcine circovirus. J Virol. 1997; 71(3):2562-6. PMC: 191374. DOI: 10.1128/JVI.71.3.2562-2566.1997. View

11.

Park K, Oh T, Yang S, Cho H, Kang I, Chae C . Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge. Vet Microbiol. 2019; 231:87-92. DOI: 10.1016/j.vetmic.2019.03.002. View

12.

Opriessnig T, Patterson A, Madson D, Pal N, Halbur P . Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-months post vaccination. Vaccine. 2008; 27(7):1002-7. DOI: 10.1016/j.vaccine.2008.11.105. View

13.

Wang F, Guo X, Ge X, Wang Z, Chen Y, Cha Z . Genetic variation analysis of Chinese strains of porcine circovirus type 2. Virus Res. 2009; 145(1):151-6. DOI: 10.1016/j.virusres.2009.05.015. View

14.

Chae C . Porcine respiratory disease complex: Interaction of vaccination and porcine circovirus type 2, porcine reproductive and respiratory syndrome virus, and Mycoplasma hyopneumoniae. Vet J. 2016; 212:1-6. DOI: 10.1016/j.tvjl.2015.10.030. View

15.

Davies B, Wang X, Dvorak C, Marthaler D, Murtaugh M . Diagnostic phylogenetics reveals a new Porcine circovirus 2 cluster. Virus Res. 2016; 217:32-7. DOI: 10.1016/j.virusres.2016.02.010. View

16.

Thacker E, Halbur P, Ross R, Thanawongnuwech R, Thacker B . Mycoplasma hyopneumoniae potentiation of porcine reproductive and respiratory syndrome virus-induced pneumonia. J Clin Microbiol. 1999; 37(3):620-7. PMC: 84495. DOI: 10.1128/JCM.37.3.620-627.1999. View

17.

Marchioro S, Sacristan R, Michiels A, Haesebrouck F, Conceicao F, Dellagostin O . Immune responses of a chimaeric protein vaccine containing Mycoplasma hyopneumoniae antigens and LTB against experimental M. hyopneumoniae infection in pigs. Vaccine. 2014; 32(36):4689-94. DOI: 10.1016/j.vaccine.2014.05.072. View

18.

Chae C . Commercial porcine circovirus type 2 vaccines: efficacy and clinical application. Vet J. 2012; 194(2):151-7. DOI: 10.1016/j.tvjl.2012.06.031. View

19.

Seo H, Han K, Oh Y, Park C, Chae C . Efficacy of a reformulated inactivated chimeric PCV1-2 vaccine based on clinical, virological, pathological and immunological examination under field conditions. Vaccine. 2012; 30(47):6671-7. DOI: 10.1016/j.vaccine.2012.08.065. View

20.

Dupont K, Nielsen E, Baekbo P, Larsen L . Genomic analysis of PCV2 isolates from Danish archives and a current PMWS case-control study supports a shift in genotypes with time. Vet Microbiol. 2007; 128(1-2):56-64. DOI: 10.1016/j.vetmic.2007.09.016. View